Evidence map›Paper›PMID 28653036›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2017

Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes.

Rachel H Tan, Jillian J Kril, Yue Yang, Nicole Tom, John R Hodges, Victor L Villemagne, Christopher C Rowe, Cristian E Leyton, John B J Kwok, Lars M Ittner and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03451760 (Feru-guard), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03451760 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Feru-guard (Ferulic Acid and Angelica Archangelica Extract) for Behavioral Symptoms in Dementia

TypeinterventionalSponsorGlovia Co., Ltd.Ran2018 to 2019Enrolled70ConditionsBehavioral and Psychiatric Symptoms of DementiaArmsFeru-guard 100M, Feru-guard 100M Placebo
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. The Role of Clinical Assessment in the Era of Biomarkers.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Connected speech markers of amyloid burden in primary progressive aphasia.Cortex; a journal devoted to the study of the nervous system and behavior · 2021
    Article
  17. Article
  18. Synergistic Association between Plasma AβACS chemical neuroscience · 2021
    Article
  19. Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Rachel H TanBrain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia.
Jillian J KrilDiscipline of Pathology, Sydney Medical School, The University of Sydney, Sydney, Australia.
Yue YangBrain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia.
Nicole TomNeuroscience Research Australia, Sydney, Australia.
John R HodgesBrain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia.
Victor L VillemagneDepartment of Molecular Imaging and Therapy, Centre for PET, Austin Health, Melbourne, Australia.
Christopher C RoweDepartment of Molecular Imaging and Therapy, Centre for PET, Austin Health, Melbourne, Australia.
Cristian E LeytonNeuroscience Research Australia, Sydney, Australia.
John B J KwokBrain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia.
Lars M IttnerSchool of Medical Sciences, University of New South Wales, Sydney, Australia.
Glenda M HallidayBrain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia.
Neuroscience Research Australia · AUUNSW Sydney · AUAustin Health · AUUniversity of Sydney · AU

Funding

Brain Tissue Resource Centre for Alcohol ResearchR28AA012725 · NIAAA · UNIVERSITY OF SYDNEY · PI Greg Trevor Sutherland · 2012 to 2026
$7.0M
NIAAA NIH HHS R28 AA012725
6 · The paper itself

Abstract

introductionThe diagnostic utility of in vivo amyloid β (Aβ) imaging to aid in the clinical distinction between frontotemporal dementia (FTD) and Alzheimer's disease remains unclear without data on the prevalence and severity of Aβ in pathologically confirmed FTD syndromes.

methodsAβ was assessed in 98 autopsy-confirmed FTD and 36 control cases, and the pathological accuracy of

resultsAβ was identified in a similar proportion of FTD syndromes and age-matched controls and increases with age. Alzheimer's disease pathology was identified in all cases with high PiB retention and in one case with low PiB retention. We further demonstrate a strong regional correlation between volume fraction of histological Aβ with PiB standard uptake value ratio scaled to the white matter. DISCUSSION: The present study provides a pathologic reference to assist in the interpretation of in vivo assessments in FTD syndromes.

Indexed as

11C-Pittsburgh compound BAlzheimer's diseaseAmyloid βDiagnosticFrontotemporal dementia syndromes

Identifiers

PMID28653036
PMCPMC5473545
OpenAlexW2617540477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.